

Intersect ENT Announces Exercise of Underwriters' Option and the Closing of Its Public Offering

Underwriters Exercise Option for 537,300 Shares of Common Stock, Increasing Total Aggregate Proceeds to Approximately \$103.0 Million

MENLO PARK, Calif.—June 8, 2015-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced the closing of its public offering of 4,119,300 shares of its common stock at a public offering price of \$25.00 per share, including 537,300 shares sold pursuant to the underwriters' option to purchase additional shares. This public offering resulted in total aggregate proceeds of approximately \$103.0 million, before underwriting discounts and expenses.

J.P. Morgan and BofA Merrill Lynch acted as joint book-running managers for the offering. Leerink Partners, Canaccord Genuity and William Blair acted as co-managers.

The registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 2, 2015. Copies of the effective registration statement, as amended, can be accessed through the SEC's website at www.sec.gov. The offering of these securities were made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by e-mail at prospectus-req_fi@jpmchase.com, or by telephone at (866) 803-9204, or from BofA Merrill Lynch, Attention: Prospectus Department, 222 Broadway, New York, NY 10038, or by e-mail at dg.prospectus_requests@baml.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Intersect ENT

Intersect ENT, Inc. is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The company markets two steroid releasing implants, PROPEL and PROPEL mini, clinically proven to improve surgical outcomes for patients with chronic sinusitis undergoing ethmoid sinus surgery. In addition, Intersect ENT is developing new steroid releasing implants designed to provide ENT physicians with customized options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections and is one of the most costly conditions to U.S. employers.

Intersect ENT, Inc.
Jeri Hilleman, 650-641-2105
ir@intersectENT.com

XENT-F